Question 1

Is LL-37 available as a supplement?

Accepted Answer

LL-37 is available through some research peptide vendors and compounding pharmacies, but it is not available as a conventional dietary supplement. It is not FDA-approved for any indication. The most evidence-based way to support your body's own LL-37 production is through vitamin D optimization, as the CAMP gene encoding LL-37 is directly regulated by vitamin D signaling.

Question 2

Can LL-37 fight antibiotic-resistant bacteria?

Accepted Answer

Yes, in laboratory studies. LL-37 has demonstrated activity against antibiotic-resistant bacteria including MRSA (methicillin-resistant Staphylococcus aureus) and multi-drug resistant Gram-negative organisms. Its mechanism — physical membrane disruption — is fundamentally different from conventional antibiotics and much harder for bacteria to develop resistance against. However, clinical use against antibiotic-resistant infections in humans has not yet been validated in large clinical trials.

Question 3

Does vitamin D increase LL-37 levels?

Accepted Answer

Yes. The CAMP gene encoding the LL-37 precursor contains a vitamin D response element in its promoter region. Active vitamin D (1,25-dihydroxyvitamin D) directly upregulates CAMP gene expression and LL-37 production. This is one of the most well-established links between vitamin D and immune function. Maintaining adequate vitamin D levels (30-50 ng/mL serum 25-hydroxyvitamin D) supports optimal LL-37 production.

Question 4

Can LL-37 worsen rosacea or psoriasis?

Accepted Answer

Potentially, yes. Excessive LL-37 expression is implicated in both rosacea and psoriasis pathogenesis. In rosacea, overexpressed LL-37 is processed into pro-inflammatory fragments. In psoriasis, LL-37 complexes with self-DNA to trigger autoimmune inflammation. Individuals with these conditions should exercise caution with exogenous LL-37 supplementation and discuss with their dermatologist.

Question 5

How is LL-37 administered?

Accepted Answer

In research and clinical trial settings, LL-37 has been administered topically (for wound healing applications), subcutaneously, and intramuscularly. Topical application avoids systemic toxicity concerns and is the most clinically advanced route. Subcutaneous injection is used in the research peptide community but carries considerations related to host cell toxicity at higher systemic concentrations. There is no oral formulation, as LL-37 would be degraded by gastrointestinal enzymes.

Question 6

What is the difference between LL-37 and other antimicrobial peptides?

Accepted Answer

LL-37 is the only human cathelicidin, but there are thousands of antimicrobial peptides across species. LL-37 is unique among human AMPs for its length (37 amino acids), alpha-helical structure, and multifunctionality — combining direct antimicrobial activity with immunomodulatory, chemotactic, and wound-healing properties. Other human AMPs, such as defensins, have different structures and somewhat different activity profiles. LL-37's broad-spectrum activity and multi-functionality make it one of the most versatile human AMPs.

Question 7

Is LL-37 the same as cathelicidin?

Accepted Answer

LL-37 is the active peptide derived from the human cathelicidin precursor protein hCAP-18. Cathelicidin refers to the broader protein family, while LL-37 is the specific active antimicrobial peptide released from the human cathelicidin precursor through enzymatic cleavage. In common usage, 'cathelicidin' and 'LL-37' are often used interchangeably when referring to the human peptide, though technically cathelicidin is the precursor and LL-37 is the processed active form.

#	Vendor	Avg score	Purity range	Tests	Verified $/mg	Grade	Profile
Grade F — Fraud
1	Reta-Peptide	—	—	0	—	F	review →
2	Qingdao Sigma Chemical QSC	—	—	0	—	F	review →

Vendor Rankings

LL-37 Rankings